Therapeutics: Phosphoinositide 3-kinase (PI3K) γ
Rat studies suggest inhibiting PI3Kγ could improve recovery following brain surgery, which can damage normal brain tissue. In rats, front-lobe corticectomy-induced brain injury increased levels of PI3Kγ and water in brain tissues and increased neurological impairments compared with no surgical injury. In the rats, a PI3Kγ inhibitor or siRNA targeting PI3Kγ administered before and after surgery decreased levels of brain water and neurological impairments compared with vehicle or scrambled siRNA, respectively. Next steps could include testing PI3Kγ inhibitors in additional models of brain injury.
Takeda Pharmaceutical Co. Ltd., AbbVie Inc. and Infinity Pharmaceuticals Inc. have duvelisib (IPI-145), an oral inhibitor of PI3Kγ and PI3Kδ, in Phase I through III testing to treat lymphomas, leukemias and inflammatory indications. ...